Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure

• Published in: Journal of viral hepatitis 2015-12, Vol.22 (12), p.992-1001
• Main Authors: Ogawa, E., Furusyo, N., Dohmen, K., Kajiwara, E., Kawano, A., Nomura, H., Takahashi, K., Satoh, T., Azuma, K., Nakamuta, M., Koyanagi, T., Kotoh, K., Shimoda, S., Hayashi, J.
• Format: Article
• Language: English
• Subjects: Aged; Antiviral Agents - therapeutic use; Carrier Proteins - genetics; Drug Therapy, Combination; Female; Hepacivirus - classification; Hepacivirus - drug effects; Hepacivirus - genetics; hepatitis C virus; Hepatitis C, Chronic - drug therapy; Humans; Interferon-alpha - therapeutic use; Japan; Liver Cirrhosis - pathology; Liver Cirrhosis - virology; Male; Middle Aged; Oligopeptides - therapeutic use; pegylated interferon; Polyethylene Glycols - therapeutic use; Recombinant Proteins - therapeutic use; Recurrence; ribavirin; Ribavirin - therapeutic use; simeprevir; Simeprevir - adverse effects; Simeprevir - therapeutic use; telaprevir; Treatment Failure; Viral Nonstructural Proteins - genetics
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.12427

Summary Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG‐IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir‐based triple therapy for patients with prior telaprevir treatment failure. This multicentre, observational cohort consisted of 345 consecutive Japanese patients infected with HCV genotype 1b, including 20 who had experienced telaprevir‐based triple therapy. Amino acid substitutions in the NS3/4A region were identified by direct sequencing at the time of relapse or breakthrough in treatment with telaprevir and at the initiation of treatment with simeprevir. Patients were stratified according to prior response to PEG‐IFNα and ribavirin. Of the 20 patients with telaprevir treatment failure, 10 (50.0%) achieved sustained virological response at week 12 after the end of treatment (SVR12). For patients treatment naïve [3/4 (75.0%)] or with prior relapse [1/1 (100%)] or partial response [5/6 (83.3%)] to PEG‐IFNα and ribavirin, almost all achieved SVR12, mainly because of the improvement of treatment adherence, especially to direct‐acting antiviral agent and ribavirin. However, of the nine patients with prior null response to PEG‐IFNα and ribavirin, only one (11.1%) achieved SVR12, despite all having received an adequate treatment dosage, and five (55.6%) achieved rapid virological response. The treatment outcome of simeprevir‐based triple therapy for HCV genotype 1b patients with prior telaprevir failure depended on the prior response to PEG‐IFNα and ribavirin. For patients with prior null response to PEG‐IFNα and ribavirin, retreatment with simeprevir‐based triple therapy is not a useful option.